This company has been marked as potentially delisted and may not be actively trading. Anchiano Therapeutics (ANCN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ANCN vs. RVPH, OKUR, IRD, AKTX, NRXP, KZR, CVKD, MRNS, FGEN, and ATHEShould you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Reviva Pharmaceuticals (RVPH), OnKure Therapeutics (OKUR), Opus Genetics (IRD), Akari Therapeutics (AKTX), NRx Pharmaceuticals (NRXP), Kezar Life Sciences (KZR), Cadrenal Therapeutics (CVKD), Marinus Pharmaceuticals (MRNS), FibroGen (FGEN), and Alterity Therapeutics (ATHE). These companies are all part of the "medical" sector. Anchiano Therapeutics vs. Reviva Pharmaceuticals OnKure Therapeutics Opus Genetics Akari Therapeutics NRx Pharmaceuticals Kezar Life Sciences Cadrenal Therapeutics Marinus Pharmaceuticals FibroGen Alterity Therapeutics Anchiano Therapeutics (NASDAQ:ANCN) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership. Do analysts prefer ANCN or RVPH? Reviva Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 1,069.32%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Anchiano Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anchiano Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Do institutionals & insiders have more ownership in ANCN or RVPH? 9.1% of Anchiano Therapeutics shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 6.9% of Anchiano Therapeutics shares are owned by insiders. Comparatively, 27.2% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, ANCN or RVPH? Anchiano Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500. Does the MarketBeat Community prefer ANCN or RVPH? Anchiano Therapeutics received 29 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 90.63% of users gave Reviva Pharmaceuticals an outperform vote while only 65.91% of users gave Anchiano Therapeutics an outperform vote. CompanyUnderperformOutperformAnchiano TherapeuticsOutperform Votes5865.91% Underperform Votes3034.09% Reviva PharmaceuticalsOutperform Votes2990.63% Underperform Votes39.38% Is ANCN or RVPH more profitable? Anchiano Therapeutics' return on equity of 36.08% beat Reviva Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Anchiano TherapeuticsN/A 36.08% 27.40% Reviva Pharmaceuticals N/A N/A -252.53% Does the media favor ANCN or RVPH? In the previous week, Reviva Pharmaceuticals had 4 more articles in the media than Anchiano Therapeutics. MarketBeat recorded 4 mentions for Reviva Pharmaceuticals and 0 mentions for Anchiano Therapeutics. Anchiano Therapeutics' average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score. Company Overall Sentiment Anchiano Therapeutics Neutral Reviva Pharmaceuticals Neutral Which has stronger valuation and earnings, ANCN or RVPH? Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnchiano TherapeuticsN/AN/A-$27.12M-$3.46-0.37Reviva PharmaceuticalsN/AN/A-$39.26M-$0.91-0.94 SummaryReviva Pharmaceuticals beats Anchiano Therapeutics on 9 of the 15 factors compared between the two stocks. Get Anchiano Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANCN vs. The Competition Export to ExcelMetricAnchiano TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.57M$6.66B$5.44B$7.81BDividend YieldN/A3.20%5.44%4.31%P/E Ratio8.607.1622.2718.38Price / SalesN/A238.87389.68101.37Price / CashN/A65.6738.2034.62Price / Book0.646.266.664.18Net Income-$27.12M$142.48M$3.21B$247.71M Anchiano Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANCNAnchiano TherapeuticsN/A$1.29+7.5%N/A+79.1%$9.57MN/A8.6016RVPHReviva Pharmaceuticals2.2521 of 5 stars$0.73-1.8%$10.00+1,266.1%-70.2%$34.21MN/A-0.665Analyst ForecastNews CoverageOKUROnKure Therapeutics2.6378 of 5 stars$2.52-7.5%$32.33+1,181.0%N/A$33.72MN/A-0.21N/AIRDOpus Genetics1.3126 of 5 stars$0.73-1.8%$7.33+907.3%N/A$33.16M$10.99M-0.6714AKTXAkari TherapeuticsN/A$1.23-3.9%N/A+22.7%$32.71MN/A0.009Positive NewsGap UpNRXPNRx Pharmaceuticals1.7667 of 5 stars$1.93+3.0%$28.25+1,366.8%-33.7%$32.58MN/A-0.902KZRKezar Life Sciences3.6717 of 5 stars$4.39+5.7%$39.50+800.6%-40.7%$32.04M$7M-0.3360CVKDCadrenal Therapeutics1.9252 of 5 stars$16.45+1.6%$32.00+94.6%N/A$30.66MN/A-2.444News CoveragePositive NewsGap UpMRNSMarinus Pharmaceuticals1.8587 of 5 stars$0.55-0.2%$4.79+771.6%-61.9%$30.32M$30.99M-0.22110FGENFibroGen4.1483 of 5 stars$0.29+2.5%$10.00+3,301.4%-67.5%$29.97M$29.62M-0.24570Analyst ForecastGap DownATHEAlterity Therapeutics1.7755 of 5 stars$3.38-2.0%$12.00+255.0%+51.9%$29.97MN/A0.0010Positive News Related Companies and Tools Related Companies RVPH Alternatives OKUR Alternatives IRD Alternatives AKTX Alternatives NRXP Alternatives KZR Alternatives CVKD Alternatives MRNS Alternatives FGEN Alternatives ATHE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANCN) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anchiano Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anchiano Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANCN Stock Free ANCN Stock Alerts